NASDAQ:DAWN

Day One Biopharmaceuticals (DAWN) Stock Forecast, Price & News

$12.51

+0.02 (+0.16%)

(As of 09/27/2023 ET)

Compare

Today's Range: $12.34
▼
$12.75
50-Day Range: $11.81
▼
$14.86
52-Week Range: $10.84
▼
$25.77

Volume: 495,647 shs
Average Volume: 910,204 shs
Market Capitalization: $1.09 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $42.14

Day One Biopharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 236.9% Upside
$42.14 Price Target
Short Interest: Bearish
21.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.81
Based on 2 Articles This Week
Insider Trading: Selling Shares
$63,562 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.45) to ($2.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

915th out of 976 stocks

Pharmaceutical Preparations Industry

431st out of 458 stocks

3.3

Analyst's Opinion

Consensus Rating
Day One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $42.14, Day One Biopharmaceuticals has a forecasted upside of 236.9% from its current price of $12.51.
Amount of Analyst Coverage
Day One Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
21.35% of the float of Day One Biopharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Day One Biopharmaceuticals has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
Change versus previous month
Short interest in Day One Biopharmaceuticals has recently increased by 2.66%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Day One Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Day One Biopharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DAWN.

1.6

News and Social Media Coverage

News Sentiment
Day One Biopharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Day One Biopharmaceuticals this week, compared to 2 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,562.00 in company stock.
Percentage Held by Insiders
Only 8.80% of the stock of Day One Biopharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($2.45) to ($2.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Day One Biopharmaceuticals is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Day One Biopharmaceuticals is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Day One Biopharmaceuticals has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DAWN Price History

30 days | 90 days | 365 days | Advanced Chart

DAWN Stock News Headlines

September 24, 2023 | fool.com

Day One Biopharmaceuticals (NASDAQ: DAWN)

September 15, 2023 | msn.com

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

September 28, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

September 12, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Day One Biopharmaceutical

September 11, 2023 | finance.yahoo.com

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

September 11, 2023 | markets.businessinsider.com

Day One Biopharmaceuticals (DAWN) Gets a Buy from H.C. Wainwright

September 11, 2023 | markets.businessinsider.com

JonesTrading Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)

August 18, 2023 | finance.yahoo.com

Jeff Bezos Used These Strategies for Business Success: Here’s Why They Work

September 28, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 16, 2023 | finance.yahoo.com

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

August 12, 2023 | markets.businessinsider.com

Day One Biopharmaceuticals (DAWN) Gets a Buy from J.P. Morgan

August 10, 2023 | finance.yahoo.com

FMR LLC Reduces Stake in Day One Biopharmaceuticals Inc

August 8, 2023 | finance.yahoo.com

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

July 23, 2023 | seekingalpha.com

Diving Into Day One Biopharmaceuticals

July 13, 2023 | seekingalpha.com

Day One Biopharmaceuticals: Uncertain Regulatory Path, Narrow Market

June 27, 2023 | benzinga.com

Board Member at Day One Biopharmaceutical Acquires Company Stock Options Worth 37,500 Shares

June 17, 2023 | finance.yahoo.com

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is favoured by institutional owners who hold 54% of the company

June 12, 2023 | finance.yahoo.com

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

June 8, 2023 | finance.yahoo.com

Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More

June 7, 2023 | msn.com

Day One Biopharmaceuticals stock dips on pricing $150M stock offering

June 7, 2023 | finance.yahoo.com

Day One Announces Pricing of Public Offering of Common Stock

June 6, 2023 | msn.com

Wedbush Reiterates Day One Biopharmaceuticals (DAWN) Outperform Recommendation

June 6, 2023 | msn.com

HC Wainwright & Co. Maintains Day One Biopharmaceuticals (DAWN) Buy Recommendation

June 5, 2023 | markets.businessinsider.com

Analyst Ratings for Day One Biopharmaceutical

June 5, 2023 | msn.com

Why Day One Biopharmaceuticals Stock Is Trading Higher Premarket Today

June 5, 2023 | seekingalpha.com

Day One climbs 16% after updating mid-stage data for lead asset

June 5, 2023 | msn.com

DAWN Rises on Promising Phase 2 data in pLGG

See More Headlines

Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DAWN Company Calendar

Last Earnings: 8/07/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DAWN
CUSIP: N/A
CIK: 1845337
Web: dayonebio.com
Phone: 650-484-0899
Fax: N/A
Employees: 124
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $42.14
High Stock Price Forecast: $54.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +236.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-142,180,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -46.75%
Return on Assets: -44.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.35
Quick Ratio: 18.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.51 per share
Price / Book: 2.77

Miscellaneous

Outstanding Shares: 86,970,000
Free Float: 79,320,000
Market Cap: $1.09 billion
Optionable: Not Optionable
Beta: -2.01

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Jeremy Bender M.B.A. (Age 51)
Ph.D., CEO, Pres & Director
Comp: $900k

Dr. Samuel C. Blackman M.D. (Age 54)
Ph.D., Co-Founder and Head of R&D
Comp: $651k

Mr. Charles N. York II (Age 46)
COO, CFO & Sec.
Comp: $715k

Dr. Mike Preigh Ph.D.
Chief of Technology Operations

Mr. Adam Dubow (Age 56)
Gen. Counsel

Ms. Jaa Roberson
Chief People Officer

Dr. Davy Chiodin Ph.D.
Pharm.D., Chief Devel. Officer

Ms. Lauren Merendino M.B.A. (Age 47)
Chief Commercial Officer

Prof. Raphael F. Rousseau M.D. (Age 54)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DAWN Stock - Frequently Asked Questions

Should I buy or sell Day One Biopharmaceuticals stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DAWN shares.
View DAWN analyst ratings or view top-rated stocks.
What is Day One Biopharmaceuticals' stock price forecast for 2023?: 8 Wall Street research analysts have issued twelve-month target prices for Day One Biopharmaceuticals' stock. Their DAWN share price forecasts range from $34.00 to $54.00. On average, they expect the company's share price to reach $42.14 in the next twelve months. This suggests a possible upside of 236.9% from the stock's current price.
View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts.
How have DAWN shares performed in 2023?: Day One Biopharmaceuticals' stock was trading at $21.52 at the start of the year. Since then, DAWN stock has decreased by 41.9% and is now trading at $12.51.
View the best growth stocks for 2023 here.
When is Day One Biopharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our DAWN earnings forecast.
How were Day One Biopharmaceuticals' earnings last quarter?: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.01.
What ETFs hold Day One Biopharmaceuticals' stock?: ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Day One Biopharmaceuticals IPO?: (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
What is Day One Biopharmaceuticals' stock symbol?: Day One Biopharmaceuticals trades on the NASDAQ under the ticker symbol "DAWN."
Who are Day One Biopharmaceuticals' major shareholders?: Day One Biopharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (8.98%), Franklin Resources Inc. (4.67%), BlackRock Inc. (4.10%), Braidwell LP (3.87%), State Street Corp (3.86%) and Goldman Sachs Group Inc. (2.75%). Insiders that own company stock include Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan.
View institutional ownership trends.
How do I buy shares of Day One Biopharmaceuticals?: Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Day One Biopharmaceuticals' stock price today?: One share of DAWN stock can currently be purchased for approximately $12.51.
How much money does Day One Biopharmaceuticals make?: Day One Biopharmaceuticals (NASDAQ:DAWN) has a market capitalization of $1.09 billion. The company earns $-142,180,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.
How many employees does Day One Biopharmaceuticals have?: The company employs 124 workers across the globe.
How can I contact Day One Biopharmaceuticals?: Day One Biopharmaceuticals' mailing address is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is dayonebio.com. The company can be reached via phone at 650-484-0899 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:DAWN) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial